Pantoprazole produces mixed results for Nycomed
02 March 2010
Christopher Spillane
Please Login to read the full article.
02 March 2010
Christopher Spillane
christopher.spillane@informa.com
Pantoprazole (Protonix) proved to be both a boon and blight on Nycomed's financial performance in 2009. The gastro-oesophageal reflux disease treatment struggled to cope with its loss of exclusivity in many key European markets, but still drove growth in Latin America.
The privately held...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Silence at Takeda and Nycomed, but a desire to expand
- Takeda-Nycomed cuts 2,800 mainly EU jobs to eliminate extra ¥10 billion in overlaps
- Yuhan touts benefits of promising new P-CAB molecule as it seeks partners
- P-CAB molecule moves ahead as Takeda looks to sustain GI franchise
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
